Comparison 1. Alemtuzumab 12 mg versus interferon beta‐1a.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Relapse‐free survival	2		Hazard Ratio (Fixed, 95% CI)	Subtotals only
1.1 24‐month analysis	2		Hazard Ratio (Fixed, 95% CI)	0.50 [0.41, 0.60]
2 Sustained disease progression‐free survival	3		Hazard Ratio (Fixed, 95% CI)	Subtotals only
2.1 24‐month analysis	2		Hazard Ratio (Fixed, 95% CI)	0.62 [0.44, 0.87]
2.2 36‐month analysis	1		Hazard Ratio (Fixed, 95% CI)	0.25 [0.11, 0.57]
3 Number of participants with at least one adverse event	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 24‐month analysis	2	1248	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [1.01, 1.06]
3.2 36‐month analysis	1	224	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.98, 1.02]
4 Change in EDSS score	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 24‐month analysis	2	1199	Mean Difference (IV, Random, 95% CI)	‐0.20 [‐0.60, 0.20]
4.2 36‐month analysis	1	223	Mean Difference (IV, Random, 95% CI)	‐0.7 [‐1.04, ‐0.36]
5 Number of participants with new or enlarging T2‐hyperintense lesions	2	1238	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.59, 0.91]
6 Number of dropouts	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 24‐months analysis	2	1248	Risk Ratio (M‐H, Fixed, 95% CI)	0.31 [0.23, 0.41]
6.2 36‐months analysis	1	224	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.57, 1.14]